Evidence map›Paper›PMID 24453765›Full record

ArticleInternational journal of MS care2013

Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.

Gael J Yonnet, Anette S Fjeldstad, Noel G Carlson, John W Rose

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of MS care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Botulinum Toxin Treatment in Multiple Sclerosis-a Review.Current treatment options in neurology · 2017
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gael J YonnetDepartment of Neurology, University of Utah, Salt Lake City, UT, USA (GJY, ASF, JWR); Neurovirology Research Laboratory, SLC-VAMC, Department of Neurology, Salt Lake City, UT, USA (NGC, JWR); and The Brain Institute, University of Utah, Salt Lake City, UT, USA (JWR).
Anette S FjeldstadDepartment of Neurology, University of Utah, Salt Lake City, UT, USA (GJY, ASF, JWR); Neurovirology Research Laboratory, SLC-VAMC, Department of Neurology, Salt Lake City, UT, USA (NGC, JWR); and The Brain Institute, University of Utah, Salt Lake City, UT, USA (JWR).
Noel G CarlsonDepartment of Neurology, University of Utah, Salt Lake City, UT, USA (GJY, ASF, JWR); Neurovirology Research Laboratory, SLC-VAMC, Department of Neurology, Salt Lake City, UT, USA (NGC, JWR); and The Brain Institute, University of Utah, Salt Lake City, UT, USA (JWR).
John W RoseDepartment of Neurology, University of Utah, Salt Lake City, UT, USA (GJY, ASF, JWR); Neurovirology Research Laboratory, SLC-VAMC, Department of Neurology, Salt Lake City, UT, USA (NGC, JWR); and The Brain Institute, University of Utah, Salt Lake City, UT, USA (JWR).
University of Utah · USCenter for Neurosciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a second-line option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time.

Identifiers

PMID24453765
PMCPMC3883006
OpenAlexW2150486106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.